18 April 2018
A delegation of eight Catalan companies from the biomedicine and health arena, most CataloniaBio & HealthTech members, participated in a business mission to Toronto (Canada) from 9 to 13 April to scout for new clients, partners and investors in one of the most advanced ecosystems in the world.
The mission —organised by ACCIÓ in collaboration with the Canadian consulate in Barcelona, Biocat and the Canadian ToHealth cluster— featured Adan Medical Innovation, Ahead Therapeutics, Althaia, INTERmedic, Inveready, Laboratorios Rubió, Mind the Byte and Reig Jofre.
The business mission coincided with Toronto Health Innovation Week (THIW), which offered more than 30 activities ...
12 April 2018
Reig Jofre has announced a €30 million investment and the triplication of the productive capacity of its Barcelona plant. The pharmaceutical group, a member of CataloniaBio & HealthTech, informs the project will imply the construction of a new building provided with state-of-the-art technologies for the manufacture of lyophilized vials and liquid vials.
It will also increase the aseptic production capacity, and will enable addressing the development and manufacture of innovative and biosimilars products (it has created the joint venture Syna Therapeutics with the biotechnology company Leanbio).
The new building for liquid and freeze-dried vials will be built inside ...
11 April 2018
The QFast® products are developed using a technology platform to detect and identify biological pathogens (salmonella, E. Coli, etc.) designed as an integrated system.
This agreement between the companies aims to promote commercial development and provide quality technical service.
11 April 2018
AB-Biotics, a CataloniaBio & HealthTech member company, has closed a deal with the Japan-based Kaneka Corporation that will give them exclusive rights in Japan and the United States. In exchange, AB-Biotics will take a percentage of the business generated in these markets.
This makes Kaneka Corporation the Catalan biotechnology firm’s largest shareholder, acquiring 34% of shares. The AB-Biotics founding partners, Miquel Àngel Bonachera and Sergi Audivert, are the second shareholders, with a 20.22% joint stake. Bonachera and Audivert noted that the operation will allow them to “accelerate growth over the coming years, with a top-notch strategic partner.” ...
10 April 2018
Vytrus Biotech, a CataloniaBio & HealthTech member company, has successfully closed the €1-million round of funding it began in the fourth quarter of 2017.
This injection of funds will allow the company to continue its expansion strategy, which includes going public on the Spanish Alternative Stock Exchange (Mercado Alternativo Bursátil - MAB) in 2019. After this increase, the company now has approximately 200 shareholders.
Vytrus Biotech was created in 2009 in Terrassa by entrepreneurs Albert Jané and Óscar Expósito as a spin-off of the University of Barcelona Faculty of Pharmacy. The company’s business is based on plant biotechnology and stem cells ...
6 April 2018
Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to evaluate the combined use of a medical device and a nutraceutical in controlling urinary pH and inhibiting crystallisation in order to prevent the calcification of double J stent catheters and reduce the number of associated complications. Each year 90,000 double J stent catheters are implanted in Spain, approximately 25% of which lead to complications.
"The calcification of a double J stent catheter implant can make surgical extraction complex, while when there are no encrustations it is an operation that lasts a few ...
6 April 2018
Multinational company Grifols, member of CataloniaBio & HealthTech, makes inroads in its research efforts to find a treatment for Alzheimer's disease. The patients enrolled in the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial have finished treatment. Thus ends the experimental phase of the trial, giving way to data collection and evaluation and analysis of the results, which the company plans to announce in the fourth quarter of 2018.
AMBAR is an international and multi-center clinical trial that included 496 patients with mild to moderate Alzheimer's disease across 41 hospitals (20 in Spain and 21 in the United States). Among ...
5 April 2018
Pharmaphenix, member of CataloniaBio & HealthTech and headquartered in the Barcelona Science Park, is celebrating its 10th anniversary. During this past decade, the consulting company has firmly positioned itself as a benchmark in emerging Latin American, Middle Eastern, South Korean, Russian and Australian markets.
In 2008, Pascal Nizet, founding partner in Spain with an extensive experience in leadership positions in the pharmaceutical industry, set up Pharmaphenix to advise healthcare companies in addressing new markets and driving their growth through expansion abroad.
Its Seoul headquarters is also celebrating its 10th anniversary, while the firm additionally has a number of ...
26 March 2018
26 March 2018
The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules.
21 March 2018
Mario Rovirosa has been named CEO of pharmaceutical company Ferrer and will take up this position on 1 April. Rovirosa is taking over for Jordi Ramentol that will continue to have ties to Ferrer as a member of the company’s board of directors.
13 March 2018
Una setantena d'emprenedors i professionals de l'àmbit de la biomedicina i la salut van participar a la jornada sobre les oportunitats internacionals en compra pública d’innovació (CPI) organitzada per ACCIÓ i CataloniaBio & HealthTech, el dia 6 de març a Barcelona.
12 March 2018
The latest edition of the Fem Talent Fòrum recognised Dr Judit Anido, CEO of Mosaic Biomedicals and member of the board at CataloniaBio & HealthTech, in the emerging talent category. Anido is the co-founder, with Dr Joan Seoane and Dr Josep Baselga, of Barcelona-based biotechnology firm Mosaic Biomedicals, which is developing personalised cancer treatments.
Another company in the biomedicine and healthcare arena, ProteoDesign, was a runner-up in the organisation category. The awards were given out in a ceremony held at Barcelona Activa Advanced Industry Park with more than 400 people in attendance. The Fem Talent awards aim to recognise ...
12 March 2018
Biotechnology company Thrombotargets has opened a round of funding looking to raise €5.5 million to complete development of its topical treatment for haemorrhages during surgery. The drug, known as TT-173, has begun phase III clinical trials. The Castelldefels-based company has been working on this product for 15 years now.
The main shareholder in Thrombotargets is Biotech Angels and the chairman of the board of directors is perfume businessman Ramón Béjar. The board of directors is formed by Ignasi Miquel, Pilar Sánchez i Jesús Murat. The company was started in 2005, developing the BioplatformScreen platform used to screen molecules. ...
9 March 2018
Yesterday, CataloniaBio & HealthTech awarded the 2018 Biosuccess Award recognising the most important business milestones in biomedicine and health in Catalonia to Anaconda Biomed and Mind the Byte.
5 March 2018
Xavier Luria is the new partner and strategy advisor of FreeOx Biotech, in a bid to accelerate development and the regulatory process for its main drug candidate, Ox-01, to treat stroke.
Luria, linked to CataloniaBio & HealthTech, is a world-renowned expert in clinical and regulatory drug development. Since 2012, he has been an independent senior consultant in Drug Development and Regulation (DDR) with offices in Barcelona and London. He was head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) from 2005 to 2012.
Xavier Luria highlights: “Given its advanced stage of development, Ox-01 could become a ...
1 March 2018
El Parc Científic de Barcelona (PCB) presenta el programa MedTeX especialitzat en l'acceleració d'empreses de recent creació en l'àmbit de les tecnologies mèdiques. En total acollirà 12 empreses, de forma gratuïta, i el termini per poder-hi optar acaba el 30 de març de 2018.
MedTeX és una oportunitat perquè els emprenedors treballin amb referents del sector per impulsar les seves empreses i assolir els objectius a través de la formació, elmentoring i el networking en l'entorn privilegiat del PCB. El PCB té una experiència acumulada de 30 empreses incubades.
El programa compta amb ...
1 March 2018
Biotechnology firm Pangaea Oncology has signed a new contract with German multinational corporation Merck, with a capital injection of more than €260,000. Specifically, Pangaea will conduct several in vitro experiments and analyse the prevalence of various genes of interest to Merck that are associated with drugs the company has in the clinical development phase. The aim is to find drug-use strategies for several subtypes of breast and lung cancer, under what is known as biomarker discovery.
Pangaea will give Merck access to its latest-generation laboratory and data-analysis capabilities to measure the prevalence in patients at its subsidiary, Dr Rosell ...
26 February 2018
The Business Council of the Vall d'Hebron Research Institute (VHIR), which includes CataloniaBIO members, met for the second time on 25 January. This board advises the VHIR directors and trustees, helping them identify opportunities, participate in joint projects and facilitate access to public and private resources.
The board has 15 members from finance, business and biotechnology, including companies and organisations such as Asebio, Fenin, Specific Pig, Grup Ferrer, ”la Caixa” Banking Foundation, AMETIC, Roche Diagnostics, Banco Sabadell, Laboratoris Esteve and Biocat. The board was created two years ago and is chaired by Lluís Bassat.
The VHIR management team presented ...